**Name of Journal: *World Journal of Hepatology***

**Manuscript NO: 29828**

**Manuscript Type: Review**

**Strategies to tackle the challenges of external beam radiotherapy for liver tumors**

Lock M *et al.* Radiotherapy strategies to treat liver tumors

**Michael I Lock, Klein Jonathan, Hans T Chung, Joseph M Herman, Edward Y Kim, William Small, Nina A Mayr, Simon S Lo**

**Michael I Lock,** Department of Radiation Oncology, London Regional Cancer Program, University of Western Ontario, London, ON N6A 3K7, Canada

**Klein Jonathan, Hans T Chung,** Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada

**Joseph M Herman,** Department of Radiation Oncology, Houston, TX 77024, United States

**Edward Y Kim**, **Nina A Mayr, Simon S Lo,** Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA 98195, United States

**William Small,** Department of Radiation Oncology, Loyola University Medical Center, Maywood, IL 60153, United States

**Author contributions:** Lock MI and Lo SS completed the primary literature review and drafting of the manuscript; all authors contributed to this paper with literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** Lo SS has received research funding from Elekta AB through the International Oligometastasis Consortium; he has also received travel expenses and honorarium from Varian Medical Systems and travel expenses from Accuray Inc.; Lock MI has received fees as a consultant or research funding from AstraZeneca Limited, Accuray Incorporated, 3M Canada, Varian Medical Systems and Abbvie Corporation. No other potential conflicts of interest are declared. No financial support.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http: //creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Michael I Lock, MD, CCFP, FRCPC, FCFP,** Department of Radiation Oncology, London Regional Cancer Program, University of Western Ontario, 790 Commissioners Rd East, London, ON N6A 4L6, Canada. michael.lock@lhsc.on.ca

**Telephone:** +1-519-6858500-52833

**Fax:** +1-519-6858627

**Received:** August 28, 2016

**Peer-review started:** August 29, 2016

**First decision:** November 21, 2016

**Revised:** April 3, 2017

**Accepted:** April 18, 2017

**Article in press:**

**Published online:**

**Abstract**

Primary and metastatic liver cancer is an increasingly common and difficult to control disease entity. Radiation offers a non-invasive treatment alternative for these patients who often have few options and a poor prognosis. However, the anatomy and aggressiveness of liver cancer poses significant challenges such as accurate localization at simulation and treatment, management of motion and appropriate selection of dose regimen. This article aims to review the options available and provide information for the practical implementation and/or improvement of liver cancer radiation programs within the context of stereotactic body radiotherapy (SBRT) and image-guided radiotherapy (IGRT) guidelines. Specific patient inclusion and exclusion criteria are presented given the significant toxicity found in certain sub-populations treated with radiation. Indeed, certain sub-populations, such as those with tumor thrombosis or those with larger lesions treated with transarterial chemoembolization (TACE), have been shown to have significant improvements in outcome with the addition of radiation and merit special consideration. Implementing a liver radiation program requires three primary challenges to be addressed: (1) immobilization and motion management; (2) localization; and (3) dose regimen and constraint selection. Strategies to deal with motion include simple internal target volume (ITV) expansions, non-gated ITV reduction strategies, breath hold methods, and surrogate marker methods to enable gating or tracking. Localization of the tumor and organs-at-risk are addressed using contrast infusion techniques to take advantage of different normal liver and cancer vascular anatomy, imaging modalities, and margin management. Finally, a dose response has been demonstrated and dose regimens appear to be converging. A more uniform approach to treatment in terms of technique, dose selection and patient selection will allow us to study liver radiation in larger and, hopefully, multicenter randomized studies.

**Key words:** Hepatocellular carcinoma; Liver metastases; Stereotactic body radiation therapy; 4DCT; Image-guided radiotherapy

**© The Author (s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Primary and metastatic liver cancer patients are a growing population seen in cancer centers. This population often has few options and a poor prognosis. Radiation offers a safe non-invasive treatment option, but those implementing a liver radiotherapy program must address specific challenges not always seen in other disease sites. A growing and large number of papers have investigated a wide range of strategies. Our objective is to consolidate this literature to provide a concise review of options to allow a pragmatic selection of management strategies.

Lock MI, Jonathan K, Chung HT, Herman JM, Kim EY, Small W, Mayr NA, Lo SS. Strategies to tackle the challenges of external beam radiotherapy for liver tumors. *World J Hepatol* 2017; In press

**INTRODUCTION**

Liver cancer is a major area of investigation as it is increasingly common and remains one of the deadliest diseases where clinicians have few options. According to Surveillance, Epidemiology, and End Results (SEER) statistics, the estimated numbers of cases of liver cancer (including intrahepatic bile duct cancers) will be 35660 in 2015 representing the second largest annual increase in incidence amongst all cancers in the United States[1]. Liver remains the most frequent site of metastatic disease for patients with colorectal cancer. Approximately 50%-60% of patients with colorectal cancer (CRC) will develop liver metastases and one third will die from liver failure from progressive disease[2]. In patients with only limited liver metastases, aggressive local treatment with surgical extirpation could result in 5-year overall survival rates of 25%-40%[2]. Likewise, the mainstay of treatment for primary liver cancer is surgical resection or liver transplantation. Unfortunately, only 15%-25% of patients are eligible for curative resection or transplant at the time of diagnosis.

Traditionally, radiotherapy has not been routinely given to patients with liver tumors primarily due to the relatively low liver tolerance to radiation. With the advent of advanced radiation technology, it is now possible to deliver potentially curative radiation doses to liver tumors safely. Investigators from Sweden and Japan pioneered the use of stereotactic body radiotherapy (SBRT), a spin-off of intracranial stereotactic radiosurgery (SRS) for extracranial targets[3]. SBRT has also been applied for the treatment of liver tumors and the early results are promising. Following these results, advanced technologies such as protons have also been used to deliver radiotherapy to liver tumors with good results[4,5].

Despite the availability of advanced radiotherapy technologies and evidence of efficacy, the use of radiotherapy for liver has not become standard[6]. This may be due to the fact that there are several difficult challenges for radiotherapy of liver lesions and a myriad of approaches to deal with these challenges. Clinicians must select an appropriate patient population, a safe and effective dose regimen, image guidance methods for tumor localization, methods to deal with respiratory motion, and methods to avoid radiation-induced complications. This overview will provide a practical review of the challenges and options for the treatment of primary and secondary liver tumors. This will assist the practical selection and implementation of options for a high-quality program that follows the guidelines on SBRT[7].

**APPROPRIATE PATIENT SELECTION AND ACHIEVABLE CLINICAL OUTCOMES**

***Hepatocellular carcinoma***

There have been significant advances in the options available for hepatocellular carcinoma beyond surgery with level 1 evidence of an overall survival benefit for sorafenib, radiofrequency ablation and TACE[2]. Patient selection for sorafenib is limited to patients with HCC, that earlier treatments options are not suitable, or patients who have progressed on other treatments. This tends to be patients with extensive disease within or outside the liver, including patients with portal vein invasion based on two randomized controlled trials[8,9]. TACE has been shown in two randomized controlled trials and one metaanalysis to improve survival at two years[10-12]. Subsequent metaanalysis has added to the controversy indicating no improvement[13]. However, there are no prospective randomized studies to inform clinical practice beyond radiofrequency ablation, sorafenib, TACE and surgery. This makes selection of appropriate patients subject to interpretation of the evidence. For radiotherapy there is no prospective randomized trial, and we must rely on interpretation of multiple studies reporting case series data with variable patient inclusion, treatment and length of follow-up (Table 1). However, the literature suggests that one subgroup can be identified: Unresectable, locally advanced disease without extrahepatic metastasis, Child-Pugh class A or B, and occupying less than 2/3 of the liver. Several guidelines already include radiation for this subgroup[14,15]. This is based on a growing body of level II evidence (retrospective and prospective case series data); this data indicates a 1-year overall survival of 48%-100%, a 1-year local control rate of 64%-100%, and a grade 3 or greater toxicity of 0%-36% (see Table 1). Yet, the role of radiation for hepatocellular carcinoma can span early curative presentations to palliative treatment also based on retrospective data[16]. For tumors near luminal structures, conventional radiotherapy may be recommended over SBRT depending on the dose selection method and planning constraints applied. For the subgroup of recurrences or incomplete responses post chemotherapy or chemoembolizations, the data also suggest that radiation is a strong option. In the landmark trial by Shim, the 2-year overall survival for those receiving radiation was 37% compared to 14% for those who did not receive radiation[17]. This trial also highlighted the importance of tumor size in predicting success of TACE and the possible value of adding for certain patients. For tumors greater than 8 and 10 cm, no patients lived beyond 2-years with TACE. However, if external beam radiation was added, the survival was 50% and 17% for the 8 and 10 cm groups, respectively. Combination therapy, particularly in those with larger lesions where TACE is indicated, the addition of radiation may play a significant role.

Lastly, another group with a very poor outcome are those with portal vein thrombosis. Radiotherapy may be particularly useful for tumor thrombosis where current median survivals remain at 2-4 mo without radiation. To date there have been twelve retrospective[18-29] and 1 prospective case[30] series demonstrating a median survival improvement of two to five times historical cohorts. The larger studies used older radiotherapy techniques, including the largest from Yoon *et al*[22]. Despite a relatively low median dose of 40 Gy in 2-5 fractions, the study achieved an impressive 43% one year overall survival and an acceptable 10% grade 3 or greater toxicity rate[22]. Randomized trials to address the value of radiation for patients with thrombosis are warranted given the possible survival benefit.

***Liver metastases***

There is growing interest in radiation for oligometastatic disease and palliation. Hoyer *et al*[31] reviewed five retrospective and seven prospective trials to determine which patients should be considered for liver SBRT. This review of the literature by a subcommittee of the American Society of Radiation Oncology (ASTRO) including members from the European Society for Therapeutic Radiology and Oncology (ESTRO), the Canadian Association of Radiation Oncology (CARO) and the Trans-Tasman Radiation Oncology Group (TROG), concluded that the ideal radiotherapy candidate would have an ECOG 0-1, possess adequate hepatic function, have no extrahepatic disease, and have an uninvolved liver volume of 700 mL or greater. This would result in local control rates ranging from 56%-100% at 2 years. Table 2 summarizes prospective trials of SBRT for liver metastases. For a large proportion, extra-hepatic progression develops after local treatment. Though no threshold dose has been found, this group recommended liver metastases receive 48 Gy in three fractions based on the available evidence.

**TECHNICAL IMPLEMENTATION CHALLENGES**

***Immobilization and motion management***

Surveys demonstrate that there is no universal standard for liver SBRT[32], but there are recommendations from large SBRT groups. This includes the CARO Scope of Practice guidelines that were published to ensure safe practice in the major SBRT sites[31,33]. In conventional treatments, a larger margin for internal target volume (ITV) may be acceptable as multiple fractions averaged the dose errors caused by inaccurate organ localization, motion or set up error. SBRT relies on the delivery of accurate high doses to the target and errors in localization could result in increased toxicity, geometric tumor miss and cannot be easily ‘corrected’ in later fractions. Therefore, the use of techniques or devices to localize the radiation to the tumor, minimize margins and optimize on-treatment quality assurance is critical. Furthermore, with the use of IMRT, improved motion management results in fewer unplanned hot and cold spots due to the interplay of the motion of anatomical structures and MLC leaf motion[34].

The primary motion with liver SBRT is respiratory motion which can be controlled with fixed immobilization, breath hold and/or tracking. For immobilization, vacuum-bag systems or fixed body immobilizers are used where arms are kept up and out of field. A simple margin expansion to account for ITV is then applied based on a 4DCT scan, fluoroscopy and/or slow CT scanning to capture the full range of motion. These are categorized as ITV methods or motion encompassing methods. An additional margin for set-up motion is added for planning target volume (PTV) with recommendations ranging between 2 and 5 mm[35]. These methods in isolation necessitate larger treated volumes, greater normal tissue inclusion and a lower chance for dose escalation. Shallow breathing may be sufficient in many patients especially if patients are compliant and can maintain regular breathing motions. The American Association of Physicists in Medicine (AAPM) Task Group 76 emphasizes that some method of respiratory assessment be applied and a step-wise algorithm be applied to determine the amount of respiratory management required[36]. However, in a large proportion of patients, additional motion management techniques are necessary to achieve greater dose escalation and safety. The AAPM suggests a cut-off of 5 mm after which respiratory management is recommended. The options can be categorized into three types: i) non-gated ITV reduction strategies, ii) active or passive breath hold techniques, and/or iii) surrogate markers. These are applied uniformly based on institutional practice or after a trial assessment of patients who are then assigned to one or more additional motion control methods.

**Non-gated ITV reduction strategies:** Abdominal compression was one of the earliest motion management strategies and was first used in Karolinska Hospital for lung and liver lesions in the 1990’s[37]. A compression plate was applied to the abdomen to reduce abdominal motion caused by respiration. Early data, primarily from lung cancer patients, has shown accuracy and reproducibility with median reductions of 7 mm[36,38]. Recent papers using fiducial markers to track motions have provided direct data on reproducibility and extent of motion reduction in liver patients using abdominal compression. Essentially, a motion minimization method, Wunderink and Méndez Romero[39] demonstrated reduced median excursion by 62% and essentially all residual excursions were reduced to less than 5 mm. Reproducibility was excellent between planning and treatment. Predating much of the 4D respiratory strategies, the appeal of this method includes better localization; this is due to more projection data from the entire breath cycle being available leading to better image quality than only a portion of the 4DCT data set. Another advantage of abdominal compression is the minimal technology requirements compared to more complicated strategies such as gating.

However, the magnitude of improvement may be smaller than initially reported. Updated data from Eccles reported in 2011 that the decrease in motion averaged 2.3 mm and 0.6 mm in the CC and AP direction; 28% saw an increase in motion with abdominal compression so this option does come with caveats[40]. Motion of other important structures such as the kidney do not appear to be improved with the use of this type of device[41]. Furthermore, not all patients require or can tolerate abdominal compression. Patients with abdominal aortic aneurysm also may not be suitable for abdominal compression. Therefore, other motion correction methods have been tested such as using the mean respiratory position for planning[42]. This strategy determines the diaphragm’s mean cranio-caudal position in the respiratory cycle or selects a mid-ventilation CT data set. Velec was able to show that this simple method resulted in a 34% lower irradiated volume due to the significantly smaller PTV compared to standard full-motion ITV-based and dose probability PTVs. However, this group demonstrated that rigid motion correction still results in an 8% and 7% change in dose accumulation for the tumor and normal tissues, respectively[43]. These changes were found in a majority of patients and suggest the need for some additional form of respiratory control and further investigation of adaptive SBRT to deal with organ deformation.

**Breath hold methods:** The second category of motion management techniques are the breath hold methods. The simplest application is deep inspiration breath hold (DIBH). Initially pioneered at the Memorial Sloan-Kettering Cancer Center[44], DIBH has shown reproducibility within a margin of 2.2 ± 2.0 mm[45]. Voluntary DIBH can reduce internal motion from 12.9 to 2.8 mm[46]. Additional margins for set-up error (typically 2-5 mm) and assessment of intra- and inter-fraction motion is required[26]. The addition of assisted or active breath hold, such as Active Breathing Control (ABC), reduces variability further. ABC was commercialized by Elekta, Inc. and uses a spirometer that monitors the phase of breathing. Usually after two preparatory breaths, a valve is closed at expiration thereby ‘holding the patient’s breath’. Issues with this strategy include concerns regarding reproducibility, cost of non-reusable components, time required, maintenance and patient tolerance. Reproducibility assessments have demonstrated good intrafraction absolute offsets of 3 mm or less. However, interfraction errors > 3 mm are found in 46% of cases further emphasizing the need for image guidance[47]. Alternatively, shallow breathing and voluntary breath hold can be monitored using the spirometry system; planning margins, treatment activation, and reproducibility of set up can be determined using the same equipment. This is useful as not all patients can tolerate active breath hold. While it has its own limitations, voluntary breath hold has many advantages compared to gating including no marker/tumor motion lag issues, about half the treatment time required, less specialized equipment, less training and software, plus more efficient simulation[29].

**Surrogate markers to enable gating or tracking:** The third variation in motion management is the use of surrogate markers to enable gating. Depending on the surrogate, this overlaps with tumor localization strategies. Surrogates are used to assess the degree of motion which leads to individualization of motion management. Compared to breath hold techniques alone, this method is better tolerated and may represent a more accurate anatomical picture than deep inspiration or expiration. External respiratory surrogates include the Varian 3D infrared marker (Real-time Positioning Management or RPM) system, the Siemens respiratory strain gauge belt, and 3D laser surface respiratory assessment systems (C-RAD Sentinel). Internal surrogates include the diaphragm/lung interface, radiotransmitters (Calypso), and radio-opaque markers (including surgical clips, stents, lipiodol or anatomical calcifications). Internal markers provide the best surrogates, but usually are invasive to insert, risk complications and have a higher relative cost in time and money. Various gating options can by chosen based on the information from these surrogates. Respiratory gating can be grouped into three major categories: First, phase gating consists of treating the patient during a particular phase such as end-expiration. The advantage is that this portion of the breathing cycle is often the most stable with the least motion. Second, amplitude gating selects a certain portion of the respiratory cycle defined by a percentage of the amplitude of each cycle. As phase gating may result in binning errors due to breath to breath variations in slope, length of cycles and amplitudes, detractors suggest better sorting with fixed amplitude gating[48]. Third, gating may be based on the surrogate marker at breath hold. In addition to motion assessment, these markers may be used during treatment for synchronizing treatment delivery. For example, simply gating the treatment beam when the surrogate indicates the tumor is in a certain position, or synchronizing the aperture via dynamic multileaf collimator (DMLC), or moving beam to the location of the lesion (Cyberknife) are valuable strategies[49]. A method to select an appropriate clinical target volume (CTV) to PTV margin has been developed by Keall and Vedam based on three challenges: (1) selection of amplitude versus phase gating; (2) accounting for phase shifts between markers and the lesion; and (3) the management of intrafraction motion versus increased delivery time[50]. Typical GTV to PTV margins are 5 mm axially and 10 mm craniocaudally[35]. Periodic monitoring during treatment is still necessary to confirm reproducibility of the motion compared to planning. Patient training plus visual or verbal prompting may allow better reproducibility and margins[50].

***Localization***

At simulation, IV contrast is considered standard particularly for hepatocellular carcinoma. However, this does introduce fusion errors as the contrast infusion must be captured over several respiratory cycles. Various protocols are in place such as the MD Anderson standardized protocol[51] or those that individualize[52] binning by visualizing contrast in specific vessels. The later method accounts for patient differences in the time contrast reaches and leaves the lesion, anatomical location of the tumor relative to the start of the scan, body weight, time-density curves and cirrhosis (Figure 1). Figure 1 demonstrates the time-density intravenous contrast enhancement called Dynamic Contrast Enhanced CT (DCECT). Images are binned by location in respiratory cycle and when the contrast density within a vessel (such as the aorta or portal vein) signifies the arterial, portal venous, and delayed phase. Images are specific to each patient and individualized contrast enhanced images (Figure 2) offer the possibility of improved delineation without additional equipment or technology, but methods to eliminate motion during the long acquisitions are required[53,54].

MRI and PET are becoming a standard part of management for liver lesions due to improved sensitivity and specificity[55]. MRI is particularly useful for small tumors, cirrhotic patients or those who are unable to tolerate IV contrast. MRI may play a greater role as experience with 4DCT, gated MRI and cine MRI accumulates[56,57]. Functional imaging assessments are useful for follow-up, and to determine the necessity to add additional treatments post radiation[58]. However, both MRI and PET have long acquisition times and require strategies to account for motion. Strategies such as multiple breath holds, parallel imaging for rapid acquisition and respiratory correlated PET are being investigated. Even if accurate localization is possible with the elimination of respiratory motion, strategies to register the MRI and/or PET to the CT image are then required. Additional margins will be required after deformable or rigid image registration in the range of 2.2 to 21.3 mm[59]. Therefore, the value of more accurate localization must be balanced against the additional margin, time, and cost.

Oral contrast is useful to localize luminal structures, which often represent the most critical organs at risk. The contrast is assigned a CT number for tissue equivalence prior to planning. Lastly, calcifications, vessels and other anatomical landmarks can be extremely useful. If possible, contouring these structures provides information to the therapists; communication with therapists to indicate which critical structures to localize, priorize and/or avoid is a practical and valuable routine to incorporate.

At treatment, localization of the tumor in the liver is sometimes not possible in contrast to other sites such as lung cancer where the tumor location is often very clear. Internal and/or external surrogate markers or structures may be used as described earlier. At treatment the consistency of correlation with respiratory motion or breath hold ability at time of simulation must be verified. A commonly used structure is the diaphragm. Vedam has shown a strong linear correlation between the diaphragm and the external marker; a superior-inferior CTV-PTV margin of 0.8 cm provided sufficient coverage over multiple sessions with or without training[60]. Static images are acceptable, but real-time or near-real-time options exist. Some systems have the ability to acquire images in fluoroscopy or cine-mode and new systems now enable almost real-time dose accumulation to enable adaptive treatment. However, with fewer fractions used in SBRT, the opportunity to correct dosing errors is limited and localization prior to and during each treatment remains the primary goal. Non-radiographic dependent internal tumor markers such as Calypso can track motion during treatment to provide a more accurate assessment of tumor motion. This real-time tracking has significant advantages over other motion control strategies including the ability to adjust beam delivery via synchronized aperture tracking methods or by directly following the lesion motion with the radiation beam.

***Dose selection and constraints***

An optimal dose for primary and secondary liver cancer has not been identified. Essentially there are two types of research approaches in the literature for dose finding: Radiobiologically-guided dose escalation and step-wise dose escalation. The first approach, such as the pioneering work of Dawson *et al*[61], uses radiobiological calculation of risk to provide individualized dose recommendations. The second relies on maximally tolerated dose (MTD) techniques used successfully in drug trials. In many cases, the dose has been determined by normal tissue constraints. Furthermore, patient tolerance of radiation may vary due to underlying hepatic insufficiency, and previous or concurrent treatments (resections, chemotherapy). Despite the varied approaches and dose regimens, a convergence of dose recommendations may be occurring [see Table 1, summary of studies for hepatocellular carcinoma (HCC); and Table 2, summary of SBRT studies of metastatic cancer]. For hepatic metastases, work published by Rusthoven demonstrated that 60 Gy in 3 fractions resulted in a local control rate of 92% at 2 years[62]. Similarly, Timmerman and Rule suggest that a 60 Gy in 5 fraction regimen is appropriate, particularly for tumors adjacent to critical structures[63]. Based on three dose escalation cohorts, the actuarial 24 month local control was 100%. The authors state that a maximum tolerated dose was not reached; MTD was defined as the dose below which the dose limiting toxicity rate was ≥ 33%. Both groups used a critical volume model with at least 700 ml of normal liver receiving less than 15 Gy and 21 Gy for the 3 and 5 fraction regimen, respectively. However, in both studies tumors were highly selected with a median tumor size of less than 3 cm and few patients had centrally located lesions. Therefore, the excellent results may not be generalizable to a wider population especially those with larger lesions. However, for patients who can meet the trial constraints, the 100% local control rate is a strong argument that the optimal dose for hepatic metastases is 60 Gy in three or five fractions.

For primary liver cancer, a dose response relationship has been found[64], but outcomes and regimens remain somewhat more varied than with metastatic disease (Table 1). HCC patient population is very heterogeneous with important parameters such as size of lesion, liver dysfunction, previous treatments received, presence of vascular invasion and number of lesions all influencing outcome. This heterogeneity increases the difficulty in generalizing data. Modeling suggests that a 90% probability of 6-mo control could be achieved with 84 Gy in 2 Gy equivalent doses[55]; much higher than the 53 Gy in 2 Gy equivalent required for metastatic disease. Review of trials reporting 2-year outcomes of greater than 90%, suggests that a dose of 45 Gy in 3-4 fractions or 35-40 Gy in 5 fractions need to be achieved (Table 1). A critical dose threshold likely exists for both local control and overall survival. In one of the larger SBRT studies, Jang *et al*[65] demonstrated that above 54 Gy in 3 fractions, local control and survival was 100% and 71% at 2-years, respectively. However, if less than 45 Gy was achieved, the local control and overall survival dropped to 64% and 30%, respectively.

Unlike patients with liver metastases, a significant proportion of patients with HCC have underlying cirrhosis and/or other insufficiency. This factor has been a consistent parameter influencing dose selection, patient selection and outcome. Most commonly measured using the Child-Pugh score, groups have consistently found this issue to influence treatment and prognosis. Cárdenes *et al*[66]. from Indiana University conducted a phase I dose escalation trial of SBRT for HCC, where 17 Child-Pugh classes A or B patients with 25 tumors were included. The initial dose level was 36 Gy in 3 fractions and there was a 2-Gy per fraction increment. Patients received a maximum of two treatments per week. The protocol required 700 cc of normal liver would receive < 15 Gy. They were able to escalate the dose to 48 Gy in 3 fractions for Child-Pugh class A patients without causing dose-limiting toxicities. However, two Child-Pugh class B patients developed grade 3 liver toxicities when the dose was escalated to 42 Gy in 3 fractions. This observation has led these investigators to change the regimen for Child-Pugh class B patients, from 40 Gy in 3 fractions to 40 Gy in 5 fractions. This was considered the MTD and no further dose escalations are recommended. The most important factor associated with grade 3 or higher liver toxicities was a Child- Pugh score of ≥ 8. Based on their experience, the group has recommended that the dose to one-third of the uninvolved liver should be restricted to ≤ 10 Gy, (3.3 Gy/ fraction) and ≥ 500 cc of uninvolved liver should receive < 7 Gy (2.3 Gy/ fraction) for Child-Pugh class A patients; for Child-Pugh class B patients, the dose to one-third of the uninvolved liver is restricted to ≤ 18 Gy, (3.6 Gy/ fraction) and ≥ 500 cc of uninvolved liver should receive < 12 Gy (2.4 Gy/ fraction)[66]. A summary of suggested constraints based on recent randomized clinical trials with accepted fraction regimens is summarized in Table 3.

**FUTURE TRENDS**

Patients with primary or secondary liver cancer are growing in incidence and have a rising mortality rate[1]. Current management with RFA, TACE, sorafenib and surgery often are not possible or result in moderate improvements[67]. Therefore, patients and their physicians must seek alternatives or combination of treatments. In addition to external beam radiation, work in the use of radionuclides, radiosensitizers (such as inhibitors of autophagy), epigenetic agents, liquid biopsies to better select patients, and immune modulation are exciting avenues of investigation. As for external beam radiotherapy, our review suggests that radiotherapy can be implemented safely and with high local control rates. In the future, we will continue to refine our technique and patient selection, but appropriate multidisciplinary randomized trials need to be completed before radiation can become a standard of care.

**CONCLUSION**

Radiation plays an important role in the treatment of primary and metastatic liver cancer. Control rates can be high and toxicity is minimal in well-selected patients. Indeed it may play a primary role in subgroups such as large tumors and those with thrombosis. The wide ranging outcomes, differing techniques and varied dosing strategies make specific treatment recommendations difficult, but the literature is converging on a short list of important components of a high quality liver radiation program. This article aims to provide a practical review of options to provide the best care possible in this evolving field.

**REFERENCES**

1. **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015; **65**: 5-29 [PMID: 25559415 DOI: 10.3322/caac.21254]
2. **Lo SS**, Moffatt-Bruce SD, Dawson LA, Schwarz RE, Teh BS, Mayr NA, Lu JJ, Grecula JC, Olencki TE, Timmerman RD. The role of local therapy in the management of lung and liver oligometastases. *Nat Rev Clin Oncol* 2011; **8**: 405-416 [PMID: 21606970 DOI: 10.1038/nrclinonc.2011.75]
3. **Lo SS**, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, Teh BS, McGarry RC, Cardenes HR, Timmerman RD. Stereotactic body radiation therapy: a novel treatment modality. *Nat Rev Clin Oncol* 2010; **7**: 44-54 [PMID: 19997074 DOI: 10.1038/nrclinonc.2009.188]
4. **Kim TH**, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Koh YH, Lee WJ, Park SJ, Kim JY, Kim DY, Kim CM. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. *Cancer Res Treat* 2015; **47**: 34-45 [PMID: 25381830 DOI: 10.4143/crt.2013.218]
5. **Hong TS**, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, Niemierko A, Wolfgang JA, Lu HM, Adams J, Weyman EA, Arellano RS, Blaszkowsky LS, Allen JN, Tanabe KK, Ryan DP, Zhu AX. A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. *Pract Radiat Oncol* 2010; **4**: 316-322 [PMID: 25194100 DOI: 10.1016/j.prro.2013.10.002]
6. **Song P**, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. *Liver Int* 2012; **32**: 1053-1063 [PMID: 22432445 DOI: 10.1111/j.1478-3231.2012.02792.x]
7. **Jaffray DA**, Langen KM, Mageras G, Dawson LA, Yan D, Edd RA, Mundt AJ, Fraass B. Safety considerations for IGRT: Executive summary. *Pract Radiat Oncol* 2013; **3**: 167-170 [PMID: 24175003 DOI: 10.1016/j.prro.2013.01.004]
8. **Cheng AL**, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; **10**: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]
9. **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
10. **Llovet JM**, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology* 2003; **37**: 429-442 [PMID: 12540794 DOI: 10.1053/jhep.2003.50047]
11. **Llovet JM**, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002; **359**: 1734-1739 [PMID: 12049862 DOI: 10.1016/SD140-6736(02)08649-X]
12. **Lo CM**, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002; **35**: 1164-1171 [PMID: 11981766 DOI: 10.1053/jhep.2002.33156]
13. **Oliveri RS**, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. *Cochrane Database Syst Rev* 2011; **(3)**: CD004787 [PMID: 21412886 DOI: 10.1002/14651858.CD004787.pub2]
14. **Park JW**. [Practice guideline for diagnosis and treatment of hepatocellular carcinoma]. *Korean J Hepatol* 2004; **10**: 88-98 [PMID: 15218342]
15. **Korean Liver Cancer Study Group and National Cancer Center, Korea**. [Practice guidelines for management of hepatocellular carcinoma 2009]. *Korean J Hepatol* 2009; **15**: 391-423 [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391]
16. **Wo JY**, Dawson LA, Zhu AX, Hong TS. An emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Surg Oncol Clin N Am* 2014; **23**: 353-368 [PMID: 24560114 DOI: 10.1016/j.soc.2013.10.007]
17. **Shim SJ**, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. *Liver Int* 2005; **25**: 1189-1196 [PMID: 16343071 DOI: 10.1111/j.1478-3231.2005.01170.x]
18. **Xi M**, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. *PLoS One* 2013; **8**: e63864 [PMID: 23737955 DOI: 10.1371/journal.pone.0063864]
19. **Lin CS**, Jen YM, Chiu SY, Hwang JM, Chao HL, Lin HY, Shum WY. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. *Jpn J Clin Oncol* 2006; **36**: 212-217 [PMID: 16613896 DOI: 10.1093/jjco/hyl006]
20. **Sugahara S**, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tsuboi K, Tokuuye K. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. *Strahlenther Onkol* 2009; **185**: 782-788 [PMID: 20013087 DOI: 10.1007/s00066-009-2020-x]
21. **Choi BO**, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, Yoon SK, Chai GY, Kang KM. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. *BMC Cancer* 2008; **8**: 351 [PMID: 19038025 DOI: 10.1186/1471-2407-8-351]
22. **Yoon SM**, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, Chung YH, Lee YS, Lee SG, Park JH, Suh DJ. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. *Int J Radiat Oncol Biol Phys* 2012; **82**: 2004-2011 [PMID: 21621346 DOI: 10.1016/j.ijrobp.2011.03.019]
23. **Chuma M**, Taguchi H, Yamamoto Y, Shimizu S, Nakanishi M, Ogawa K, Sho T, Horimoto H, Kobayashi T, Nakai M, Terashita K, Sakuhara Y, Abo D, Tsukuda Y, Tsunematsu S, Hige S, Kato M, Shirato H, Asaka M. Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. *J Gastroenterol Hepatol* 2011; **26**: 1123-1132 [PMID: 21501224 DOI: 10.1111/j.1440-1746.2011.06745.x]
24. **Hata M**, Tokuuye K, Sugahara S, Kagei K, Igaki H, Hashimoto T, Ohara K, Matsuzaki Y, Tanaka N, Akine Y. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. *Cancer* 2005; **104**: 794-801 [PMID: 15981284 DOI: 10.1002/cncr.21237]
25. **Shirai S**, Sato M, Suwa K, Kishi K, Shimono C, Kawai N, Tanihata H, Minamiguchi H, Nakai M. Single photon emission computed tomography-based three-dimensional conformal radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus. *Int J Radiat Oncol Biol Phys* 2009; **73**: 824-831 [PMID: 18755560 DOI: 10.1016/j.ijrobp.2008.04.055]
26. **Huang YJ**, Hsu HC, Wang CY, Wang CJ, Chen HC, Huang EY, Fang FM, Lu SN. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2009; **73**: 1155-1163 [PMID: 18760547 DOI: 10.1016/j.ijrobp.2008.06.1486]
27. **Nakagawa K**, Yamashita H, Shiraishi K, Nakamura N, Tago M, Igaki H, Hosoi Y, Shiina S, Omata M, Makuuchi M, Ohtomo K. Radiation therapy for portal venous invasion by hepatocellular carcinoma. *World J Gastroenterol* 2005; **11**: 7237-7241 [PMID: 16437621 DOI: 10.3748/wjg.v11.i46.7237]
28. **Kim DY**, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, Kho KC, Kim TH, Ahn YC, Huh SJ. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. *Cancer* 2005; **103**: 2419-2426 [PMID: 15822130 DOI: 10.1002/cncr.21043]
29. **Zeng ZC**, Fan J, Tang ZY, Zhou J, Qin LX, Wang JH, Sun HC, Wang BL, Zhang JY, Jiang GL, Wang YQ. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. *Int J Radiat Oncol Biol Phys* 2005; **61**: 432-443 [PMID: 15667964 DOI: 10.1016/j.ijrobp.2004.05.025]
30. **Bujold A**, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. *J Clin Oncol* 2013; **31**: 1631-1639 [PMID: 23547075 DOI: 10.1200/jco.2012.44.1659]
31. **Høyer M**, Swaminath A, Bydder S, Lock M, Méndez Romero A, Kavanagh B, Goodman KA, Okunieff P, Dawson LA. Radiotherapy for liver metastases: a review of evidence. *Int J Radiat Oncol Biol Phys* 2012; **82**: 1047-1057 [PMID: 22284028 DOI: 10.1016/j.ijrobp.2011.07.020]
32. **Lock MI**, Hoyer M, Bydder SA, Okunieff P, Hahn CA, Vichare A, Dawson LA. An international survey on liver metastases radiotherapy. *Acta Oncol* 2012; **51**: 568-574 [PMID: 22559157 DOI: 10.3109/0284186X.2012.681700]
33. **Sahgal A**, Roberge D, Schellenberg D, Purdie TG, Swaminath A, Pantarotto J, Filion E, Gabos Z, Butler J, Letourneau D, Masucci GL, Mulroy L, Bezjak A, Dawson LA, Parliament M. The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. *Clin Oncol* (R Coll Radiol) 2012; **24**: 629-639 [PMID: 22633542 DOI: 10.1016/j.clon.2012.04.006]
34. **Yu CX**, Jaffray DA, Wong JW. The effects of intra-fraction organ motion on the delivery of dynamic intensity modulation. *Phys Med Biol* 1998; **43**: 91-104 [PMID: 9483625 DOI: 10.1088/0031-9155/43/1/006]
35. **Cárdenes HR**, Lasley F. Primary liver cancer. In: Lo SS, Teh BS, Lu JJ, Schefter TE (Eds.). Stereotactic body radiation therapy. Berlin: Springer-Verlag, 2012: 163-182 [DOI: 10.1007/174\_2012\_548]
36. **Keall PJ**, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, Kapatoes JM, Low DA, Murphy MJ, Murray BR, Ramsey CR, Van Herk MB, Vedam SS, Wong JW, Yorke E. The management of respiratory motion in radiation oncology report of AAPM Task Group 76. *Med Phys* 2006; **33**: 3874-3900 [PMID: 17089851 DOI: 10.1118/1.2349696]
37. **Lax I**, Blomgren H, Näslund I, Svanström R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. *Acta Oncol* 1994; **33**: 677-683 [PMID: 7946448 DOI: 10.3109/02841869409121782]
38. **Herfarth KK**, Debus J, Lohr F, Bahner ML, Fritz P, Höss A, Schlegel W, Wannenmacher MF. Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. *Int J Radiat Oncol Biol Phys* 2000; **46**: 329-335 [PMID: 10661339 DOI: 10.1016/S0360-3016(99)00413-7]
39. **Wunderink W**, Méndez Romero A, de Kruijf W, de Boer H, Levendag P, Heijmen B. Reduction of respiratory liver tumor motion by abdominal compression in stereotactic body frame, analyzed by tracking fiducial markers implanted in liver. *Int J Radiat Oncol Biol Phys* 2008; **71**: 907-915 [PMID: 18514783 DOI: 10.1016/j.ijrobp.2008.03.010]
40. **Eccles CL**, Patel R, Simeonov AK, Lockwood G, Haider M, Dawson LA. Comparison of liver tumor motion with and without abdominal compression using cine-magnetic resonance imaging. *Int J Radiat Oncol Biol Phys* 2011; **79**: 602-608 [PMID: 20675063 DOI: 10.1016/j.ijrobp.2010.04.028]
41. **Heinzerling JH**, Anderson JF, Papiez L, Boike T, Chien S, Zhang G, Abdulrahman R, Timmerman R. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. *Int J Radiat Oncol Biol Phys* 2008; **70**: 1571-1578 [PMID: 18374231 DOI: 10.1016/j.ijrobp.2007.12.023]
42. **Velec M**, Moseley JL, Brock KK. Simplified strategies to determine the mean respiratory position for liver radiation therapy planning. *Pract Radiat Oncol* 2014; **4**: 160-166 [PMID: 24766682 DOI: 10.1016/j.prro.2013.07.001]
43. **Velec M**, Moseley JL, Eccles CL, Craig T, Sharpe MB, Dawson LA, Brock KK. Effect of breathing motion on radiotherapy dose accumulation in the abdomen using deformable registration. *Int J Radiat Oncol Biol Phys* 2011; **80**: 265-272 [PMID: 20732755 DOI: 10.1016/j.ijrobp.2010.05.023]
44. **Mageras GS**, Yorke E. Deep inspiration breath hold and respiratory gating strategies for reducing organ motion in radiation treatment. *Semin Radiat Oncol* 2004; **14**: 65-75 [PMID: 14752734 DOI: 10.1053/j.semradonc.2003.10.009]
45. **Brock KK**. Imaging and image-guided radiation therapy in liver cancer. *Semin Radiat Oncol* 2011; **21**: 247-255 [PMID: 21939853 DOI: 10.1016/j.semradonc.2011.05.001]
46. **Barnes EA**, Murray BR, Robinson DM, Underwood LJ, Hanson J, Roa WH. Dosimetric evaluation of lung tumor immobilization using breath hold at deep inspiration. *Int J Radiat Oncol Biol Phys* 2001; **50**: 1091-1098 [PMID: 11429237 DOI: 10.1016/S0360-3016(01)01592-9]
47. **Eccles C**, Brock KK, Bissonnette JP, Hawkins M, Dawson LA. Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. *Int J Radiat Oncol Biol Phys* 2006; **64**: 751-759 [PMID: 16458774 DOI: 10.1016/j.ijrobp.2005.05.066]
48. **Wink N**, Panknin C, Solberg TD. Phase versus amplitude sorting of 4D-CT data. *J Appl Clin Med Phys* 2006; **7**: 77-85 [PMID: 16518319 DOI: 10.1120/jacmp.2027.25373]
49. **Keall P**. 4-dimensional computed tomography imaging and treatment planning. *Semin Radiat Oncol* 2004; **14**: 81-90 [PMID: 14752736 DOI: 10.1053/j.semradonc.2003.10.006]
50. **Vedam SS**, Keall PJ, Kini VR, Mohan R. Determining parameters for respiration-gated radiotherapy. *Med Phys* 2001; **28**: 2139-2146 [PMID: 11695776 DOI: 10.1118/1.1406524]
51. **Beddar AS**, Briere TM, Balter P, Pan T, Tolani N, Ng C, Szklaruk J, Krishnan S. 4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. *Radiother Oncol* 2008; **87**: 445-448 [PMID: 18194819 DOI: 10.1016/j.radonc.2007.12.009]
52. **Ichikawa T**, Erturk SM, Araki T. Multiphasic contrast-enhanced multidetector-row CT of liver: contrast-enhancement theory and practical scan protocol with a combination of fixed injection duration and patients' body-weight-tailored dose of contrast material. *Eur J Radiol* 2006; **58**: 165-176 [PMID: 16417983 DOI: 10.1016/j.ejrad.2005.11.037]
53. **Jensen NK**, Mulder D, Lock M, Fisher B, Zener R, Beech B, Kozak R, Chen J, Lee TY, Wong E. Dynamic contrast enhanced CT aiding gross tumor volume delineation of liver tumors: an interobserver variability study. *Radiother Oncol* 2014; **111**: 153-157 [PMID: 24631143 DOI: 10.1016/j.radonc.2014.01.026]
54. **Jensen NK**, Stewart E, Lock M, Fisher B, Kozak R, Chen J, Lee TY, Wong E. Assessment of contrast enhanced respiration managed cone-beam CT for image guided radiotherapy of intrahepatic tumors. *Med Phys* 2014; **41**: 051905 [PMID: 24784384 DOI: 10.1118/1.4870385]
55. **Hussain SM**, Semelka RC. Hepatic imaging: comparison of modalities. *Radiol Clin North Am* 2005; **43**: 929-47, ix [PMID: 16098348 DOI: 10.1016/j.rcl.2005.05.006]
56. **Yu JI**, Kim JS, Park HC, Lim DH, Han YY, Lim HC, Paik SW. Evaluation of anatomical landmark position differences between respiration-gated MRI and four-dimensional CT for radiation therapy in patients with hepatocellular carcinoma. *Br J Radiol* 2013; **86**: 20120221 [PMID: 23239694 DOI: 10.1259/bjr.20120221]
57. **Liu Y**, Yin FF, Chen NK, Chu ML, Cai J. Four dimensional magnetic resonance imaging with retrospective k-space reordering: a feasibility study. *Med Phys* 2015; **42**: 534-541 [PMID: 25652474 DOI: 10.1118/1.4905044]
58. **Huang WY**, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. *J Nucl Med* 2013; **54**: 1710-1716 [PMID: 23970365 DOI: 10.2967/jnumed.112.119370]
59. **Voroney JP**, Brock KK, Eccles C, Haider M, Dawson LA. Prospective comparison of computed tomography and magnetic resonance imaging for liver cancer delineation using deformable image registration. *Int J Radiat Oncol Biol Phys* 2006; **66**: 780-791 [PMID: 17011453 DOI: 10.1016/j.ijrobp.2006.05.035]
60. **Vedam SS**, Kini VR, Keall PJ, Ramakrishnan V, Mostafavi H, Mohan R. Quantifying the predictability of diaphragm motion during respiration with a noninvasive external marker. *Med Phys* 2003; **30**: 505-513 [PMID: 12722802 DOI: 10.1118/1.1558675]
61. **Tse RV**, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Clin Oncol* 2008; **26**: 657-664 [PMID: 18172187 DOI: 10.1200/JCO.2007.14.3529]
62. **Rusthoven KE**, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. *J Clin Oncol* 2009; **27**: 1572-1578 [PMID: 19255321 DOI: 10.1200/JCO.2008.19.6329]
63. **Rule W**, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, Schwarz RE, Weatherall P, Chinsoo Cho L. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. *Ann Surg Oncol* 2011; **18**: 1081-1087 [PMID: 21046264 DOI: 10.1245/s10434-010-1405-5]
64. **Lausch A**, Sinclair K, Lock M, Fisher B, Jensen N, Gaede S, Chen J, Wong E. Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours. *Br J Radiol* 2013; **86**: 20130147 [PMID: 23690438 DOI: 10.1259/bjr.20130147]
65. **Jang WI**, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, Kang JK, Kim SY, Lee DH, Han CJ, Kim J, Park SC, Kim SB, Cho EH, Kim YH. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. *Radiat Oncol* 2013; **8**: 250 [PMID: 24160944 DOI: 10.1186/1748-717X-8-250]
66. **Cárdenes HR**, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone PA. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. *Clin Transl Oncol* 2010; **12**: 218-225 [PMID: 20231127 DOI: 10.1007/s12094-010-0492-x]
67. **Ohri N**, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. *J Natl Cancer Inst* 2016; **108**: [PMID: 27377923]
68. **Scorsetti M**, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, Navarria P, Fogliata A, Tomatis S, D'Agostino G, Iftode C, Mancosu P, Ceriani R, Torzilli G. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). *J Cancer Res Clin Oncol* 2015; **141**: 1301-1309 [PMID: 25644863 DOI: 10.1007/s00432-015-1929-y]
69. **Yamashita H**, Onishi H, Murakami N, Matsumoto Y, Matsuo Y, Nomiya T, Nakagawa K. Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. *J Radiat Res* 2015; **56**: 561-567 [PMID: 25691453 DOI: 10.1093/jrr/rru130]
70. **Huertas A**, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croisé-Laurent V, Barraud H, Ayav A, Bronowicki JP, Peiffert D. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. *Radiother Oncol* 2015; **115**: 211-216 [PMID: 26028227 DOI: 10.1016/j.radonc.2015.04.006]
71. **Zhong NB**, Lv GM, Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (≥10 cm) hepatocellular carcinomas: A clinical study. *Mol Clin Oncol* 2014; **2**: 839-844 [PMID: 25054055 DOI: 10.3892/mco.2014.304]
72. **Lo CH**, Huang WY, Lee MS, Lin KT, Lin TP, Chang PY, Fan CY, Jen YM. Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who failed or were unsuitable for transarterial chemoembolization. *Eur J Gastroenterol Hepatol* 2014; **26**: 345-352 [PMID: 24384685 DOI: 10.1097/meg.0000000000000032]
73. **Van De Voorde L**, Vanneste B, Houben R, Damen P, van den Bogaard J, Lammering G, Dejong K, de Vos-Geelen J, Buijsen J, Öllers M, Berbée M, Lambin P. Image-guided stereotactic ablative radiotherapy for the liver: a safe and effective treatment. *Eur J Surg Oncol* 2015; **41**: 249-256 [PMID: 25468743 DOI: 10.1016/j.ejso.2014.10.053]
74. **Takeda A**, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, Mizuno T, Yashiro K, Nisimura S, Kunieda E. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. *J Gastroenterol Hepatol* 2014; **29**: 372-379 [PMID: 23927053 DOI: 10.1111/jgh.12350]
75. **Park JH**, Yoon SM, Lim YS, Kim SY, Shim JH, Kim KM, Lee HC, Cho B, Park G, Kim JH. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma. *J Gastroenterol Hepatol* 2013; **28**: 1638-1642 [PMID: 23621519 DOI: 10.1111/jgh.12249]
76. **Yoon SM**, Lim YS, Park MJ, Kim SY, Cho B, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Lee SG, Lee YS, Park JH, Kim JH. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. *PLoS One* 2013; **8**: e79854 [PMID: 24255719 DOI: 10.1371/journal.pone.0079854]
77. **Jung J**, Yoon SM, Kim SY, Cho B, Park JH, Kim SS, Song SY, Lee SW, Ahn SD, Choi EK, Kim JH. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. *Radiat Oncol* 2013; **8**: 249 [PMID: 24160910 DOI: 10.1186/1748-717X-8-249]
78. **Bibault JE**, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, Lacornerie T, Lartigau E, Mirabel X. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. *PLoS One* 2013; **8**: e77472 [PMID: 24147002 DOI: 10.1371/journal.pone.0077472]
79. **Honda Y**, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Naeshiro N, Ono A, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Ishikawa M, Kakizawa H, Kenjo M, Takahashi S, Awai K, Nagata Y, Chayama K. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. *J Gastroenterol Hepatol* 2013; **28**: 530-536 [PMID: 23216217 DOI: 10.1111/jgh.12087]
80. **Yuan Z**, Tian L, Wang P, Song Y, Dong Y, Zhuang H. Comparative research on the efficacy of CyberKnife® and surgical excision for Stage I hepatocellular carcinoma. *Onco Targets Ther* 2013; **6**: 1527-1532 [PMID: 24194645 DOI: 10.2147/ott.S51452]
81. **Sanuki N**, Takeda A, Mizuno T, Oku Y, Eriguchi T, Iwabuchi S, Kunieda E. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. *AJR Am J Roentgenol* 2013; **201**: W812-W820 [PMID: 24261388 DOI: 10.2214/AJR.12.10169]
82. **Huang WY**, Jen YM, Lee MS, Chang LP, Chen CM, Ko KH, Lin KT, Lin JC, Chao HL, Lin CS, Su YF, Fan CY, Chang YW. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2012; **84**: 355-361 [PMID: 22342300 DOI: 10.1016/j.ijrobp.2011.11.058]
83. **Kang JK**, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, Jung DH, Kim KB, Lee DH, Han CJ, Kim J, Park SC, Kim YH. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. *Cancer* 2012; **118**: 5424-5431 [PMID: 22570179 DOI: 10.1002/cncr.27533]
84. **Ibarra RA**, Rojas D, Snyder L, Yao M, Fabien J, Milano M, Katz A, Goodman K, Stephans K, El-Gazzaz G, Aucejo F, Miller C, Fung J, Lo S, Machtay M, Sanabria JR. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. *Acta Oncol* 2012; **51**: 575-583 [PMID: 22263926 DOI: 10.3109/0284186X.2011.652736]
85. **Price TR**, Perkins SM, Sandrasegaran K, Henderson MA, Maluccio MA, Zook JE, Tector AJ, Vianna RM, Johnstone PA, Cardenes HR. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. *Cancer* 2012; **118**: 3191-3198 [PMID: 22025126 DOI: 10.1002/cncr.26404]
86. **Andolino DL**, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR. Stereotactic body radiotherapy for primary hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2011; **81**: e447-e453 [PMID: 21645977 DOI: 10.1016/j.ijrobp.2011.04.011]
87. **Chan LC**, Chiu SK, Chan SL. Stereotactic radiotherapy for hepatocellular carcinoma: report of a local single-centre experience. *Hong Kong Med J* 2011; **17**: 112-118 [PMID: 21471590]
88. **Louis C**, Dewas S, Mirabel X, Lacornerie T, Adenis A, Bonodeau F, Lartigau E. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. *Technol Cancer Res Treat* 2010; **9**: 479-487 [PMID: 20815419 DOI: 10.1177/153303461000900506]
89. **Kwon JH**, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. *BMC Cancer* 2010; **10**: 475 [PMID: 20813065 DOI: 10.1186/1471-2407-10-475]
90. **Son SH**, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, Yoon SK, Choi IB, Kang KM, Jang HS. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. *Int J Radiat Oncol Biol Phys* 2010; **78**: 1073-1080 [PMID: 20207492 DOI: 10.1016/j.ijrobp.2009.09.009]
91. **Goyal K**, Einstein D, Yao M, Kunos C, Barton F, Singh D, Siegel C, Stulberg J, Sanabria J. Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: preliminary results. *HPB Surg* 2010; **2010**: [PMID: 20689733 DOI: 10.1155/2010/309780]
92. **Seo YS**, Kim MS, Yoo SY, Cho CK, Choi CW, Kim JH, Han CJ, Park SC, Lee BH, Kim YH, Lee DH. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. *J Surg Oncol* 2010; **102**: 209-214 [PMID: 20740576 DOI: 10.1002/jso.21593]
93. **Méndez Romero A**, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, Levendag PC. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. *Acta Oncol* 2006; **45**: 831-837 [PMID: 16982547 DOI: 10.1080/02841860600897934]
94. **Herfarth KK**, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Höss A, Schlegel W, Wannenmacher MF. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. *J Clin Oncol* 2001; **19**: 164-170 [PMID: 11134209 DOI: 10.1200/JCO.2001.19.1.164]
95. **Hoyer M**, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, Kiil Berthelsen A, Grau C, Aage Engelholm S, Von der Maase H. Phase II study on stereotactic body radiotherapy of colorectal metastases. *Acta Oncol* 2006; **45**: 823-830 [PMID: 16982546 DOI: 10.1080/02841860600904854]
96. **Kavanagh BD**, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, Gaspar LE. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. *Acta Oncol* 2006; **45**: 848-855 [PMID: 16982549 DOI: 10.1080/02841860600904870]
97. **Ambrosino G**, Polistina F, Costantin G, Francescon P, Guglielmi R, Zanco P, Casamassima F, Febbraro A, Gerunda G, Lumachi F. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. *Anticancer Res* 2009; **29**: 3381-3384 [PMID: 19661360]
98. **Lee MT**, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, Cummings B, Ringash J, Tse RV, Knox JJ, Dawson LA. Phase I study of individualized stereotactic body radiotherapy of liver metastases. *J Clin Oncol* 2009; **27**: 1585-1591 [PMID: 19255313 DOI: 10.1200/JCO.2008.20.0600]
99. **Stintzing S**, Hoffmann RT, Heinemann V, Kufeld M, Rentsch M, Muacevic A. Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. *Ann Surg Oncol* 2010; **17**: 2877-2883 [PMID: 20574773 DOI: 10.1245/s10434-010-1187-9]
100. **Goodman KA**, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. *Int J Radiat Oncol Biol Phys* 2010; **78**: 486-493 [PMID: 20350791 DOI: 10.1016/j.ijrobp.2009.08.020]
101. **Janoray G**, Chapet S, Ruffier-Loubière A, Bernadou G, Pointreau Y, Calais G. Robotic stereotactic body radiation therapy for tumors of the liver: radiation-induced liver disease, incidence and predictive factors. *Cancer Radiother* 2014; **18**: 191-197 [PMID: 24837351 DOI: 10.1016/j.canrad.2014.03.009]
102. **University of Aarhus**. Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases (RAS01). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: URL: http: //clinicaltrials.gov/ct2/show/NCT01233544 NLM Identifier: NCT01233544
103. **University Health Network, Toronto**. Sorafenib-RT Treatment for Liver Metastasis (SLIM). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: URL: http: //clinicaltrials.gov/ct2/show/NCT00892424 NLM Identifier: NCT00892424
104. **Bentzen SM**, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. *Int J Radiat Oncol Biol Phys* 2010; **76**: S3-S9 [PMID: 20171515 DOI: 10.1016/j.ijrobp.2009.09.040]



**Figure 1 Image of a time-density intravenous contrast enhancement called Dynamic Contrast Enhanced computerized tomography.** Images are binned by location in respiratory cycle and when the contrast density within a vessel (such as the aorta and portal vein) signifies the non-contrast, arterial and wash-out phase.



**Figure 2 Arterial and portal-venous phase images.**

**Table 1 Summary of hepatocellular carcinoma radiotherapy studies**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Source, year** | **Number of patients** | **% of Child-Pugh B patients** | **Median tumor diameter (range), cm** | **Dose (range)/**  **Number of fractions** | **Median follow up interval, mo** | **1-yr OS** | **2-yr LC** | **Toxicity** |
| Scorsetti[68], 2015 | 43 | 36% | ≤ 6 cm | 48-75 Gy/3 (51%) and 36-60 Gy/6 (49%) | 8 | 77.9% | 64.4% | ≥ gr3: 0 |
| Yamashita[69], 2015 | 79 | 11% | 2.7 cm | 48 Gy (40-60)/4-10 | 21 | 53% at 2 yr | 40% | gr3-4: 4.6% gr2: 2.3% |
| Huertas[70], 2015 | 77 | 14.3% | 2.4 cm | 45 Gy/3 | 12 | 81.8 | 99% | 14.9% |
| Zhong[71], 2014 | 72 | 26% | 13.1 cm | 35.6 Gy/12 | 18 | 56% | NR | gr1-2: 5.6% liver  gr1-2: 9.8% gastrointestinal |
| Lo[72], 2014 | 53 | NR | 4.3 cm | 40 Gy/4-5 | 13.1 | 70.1% |  | RILD 9.4% |
| Van de Voorde[73], 2014 | 5 | NR | NR | 93.6 Gy (62.5-150 )/3-10 | 21 | 85.4% | NR | 0 | |
| Sanuki[74], 2014 | 63 | 16% | 2.6 cm | 35-40 Gy/5 | 31.1 | 100% | 95% | gr3:  early: 16%  late: 21%  gr4-5: 0% |
| Park[75], 2013 | 26 | 27% | 2.8 cm | 40-50 Gy; 4-5 Gy per fraction | 20.2 | 88.5% | 87.6% | gr3: 4%  gr4-5: 0% |
| Bujold[30], 2013 | 102 | 0% | 9.9 cm | 24-54 Gy (36)/6 | 31.4 | 75% | 74% | gr3: 21% gr4: 2.9% gr5: 6.9% |
| Yoon[76], 2013 | 93 | 26% | 2 cm | 45 Gy (30-60)/3-4 | 25.6 | 86.0% | 94.8%1 (2 yr) | gr3: 4.3%  gr4: 1.0%  gr5: 1.0% |
| Jang[65], 2013 | 108 | 10% | 3.0 cm | 51 Gy (33-60 )/3 | 30 | 83%1 | 87% | gr3: 6.5%  gr4: 1.9%  gr5: 0% |
| Jung[77], 2013 | 92 | 26% | Vol: 8.6 cc | 45 Gy (30-60 )/3-4 | 25.7 | 86.9% | 92.1% (3 yr) | gr≥3: 7% |
| Bibault[78], 2013 | 75 | 11% | 3.7 cm | 40-45 Gy /3 | 10 | 78.5% | 89.8% | gr3: 4%  gr4: 1.3%  gr5: 0% |
| Honda[79], 2013 | 30 | 23% | 16 cm | 48 Gy /4 | 12.3 ( | 100% | 95%1 | gr3: 10%  gr4-5: 0% |
| Yuan[80], 2013 | 22 | 45% | 4.3 cm | 45 Gy (39-54)/3-8 | 53.4 | 73% | 92.9% | gr2: 31.8% |
| Sanuki[81], 2013 | 185 | 15% | CP-A: 27 cm  CP-B: 24 cm | CP-A: 40 Gy /5  CP-B: 35 Gy /5 | 24 | 95% | 93% (2 yr) | gr5: 1.1% |
| Xi[18], 2013 | 41 | 0% | Mean GTV vol: 65.4 cc (SD: 47.9) | 30-48 Gy (36) | 10 | 50.3% | NR | gr3: 2.4%  gr4-5: 0% |
| Huang[82],  2012 | 36 | NR | 1.1-12.3 cm | 37 Gy (25-48)/4-5 | 14 | 64% at 2 yrs | 98% | gr2: 3% |
| Kang[83], 2012 | 47 | 13% | 2.9 cm | 42-60 Gy /3 | 17 | 83%1 | 94.6% | gr3: 6.4%  gr4: 4.3%  gr5: 0% |
| Ibarra[84], 2012 | 21 | NR | GTV vol: 334.2 cc | 30 Gy (18-50 )/1-10 | 12.9 | 87% | 57%1 (2 yr) | gr3: 4.8%  gr4: 4.8%  gr5: 0% |
| Price[85], 2012 | 26 | 46% | Median GTV vol: 33.9 cc | 42 Gy (24-48 )/3-5 | 13 | 77% | NR | NR |
| Andolino[86], 2011 | 60 | 40% | 3.1 cm | CP-A: 30-48 Gy /3  CP-B: 24-48 Gy /5 | 27 | 82%1 | 90% (2 yr) | gr3: 35%  gr4: 1.7%  gr5: 0% |
| Chan[87], 2011 | 11 | 25% | 3 cm | 45 Gy /10 | 24 | 62% | NR | gr≥3 22% |
| Louis[88], 2010 | 25 | 12% | 4.5 cm | 45 Gy /3 | 12.7 | 79% | 95% | gr3:  early 8%  late 4% |
| Kwon[89], 2010 | 42 | 10% | Vol: 15.4 cc | 30-39 Gy /3 | 28.7 | 92.9% | 67.5% | gr3: 0%  gr4: 2%  gr5: 0% |
| Cárdenes[66], 2010 | 17 | 65% | ≤ 6 cm | CP-A: 48 Gy /3  CP-B: 42 Gy /3 then 40/5 | 24 | 75% | 100% | gr3: 13 instances  gr4: 11.8%  gr5: 0% |
| Son[90], 2010 | 47 | 8% | 18.3 cm | 36 Gy (30-39)/3 | NR | NR | NR | gr2: 33% |
| Goyal[91], 2010 | 6 | NR | 9.3 cm | 34 (24-45 Gy)/1-3 | 10 | 83% | 100% at 9 mo | 0% |
| Seo[92], 2010 | 38 | 11% | Vol: 40.5 cc | 33-57 Gy /3-4 | 15 | 68.4% | 66.4% (local PFS) | gr3: 3%  gr4-5: 0% |
| Choi[21], 2008 | 22 | 14% | Vol: 23.5 cc | 36 Gy (30-39 )/3 | 11.5 | 88.1% | NR | gr3: 4.5%  gr4-5: 0% |
| Tse[61], 2008 | 31 | 0% | 173 cc | 36 Gy (24-54 )/6 | 17.6 | 48% | NR | gr3: 29% gr4-5: 0% |
| Méndez Romero[93], 2006 | 8 | 25% | 3.2 cm | < 4 cm: 37.5 Gy /3  ≥ 4 cm: 25 Gy /5 or 30 Gy /3 | 12.9 | 75% | 75% (22 mo) | gr5: 12.5% RILD |

1Estimated from survival curve. CP-A: Child-Pugh class A; CP-B: Child-Pugh class B; gr: Grade; GTV: Gross tumor volume; LC: Local control; OS: Overall survival; NR: Not reported; PFS: Progression-free survival; RILD: Radiation induced liver disease; vol: Volume.

**Table 2 Prospective metastatic liver SBRT studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **Number of patients** | **Dose (Gy/fraction)** | **Median follow-up (mo)** | **2-yr local control (%)** |
| Herfarth[94],  (2001) | 37 | 14-26 Gy/1 | 5.7 | 812 |
| Hoyer[95], (2006) | 44 | 45 Gy/3 | 51.6 | 79 |
| Kavanagh[96], (2006) | 36 | 60 Gy/3 | 19 | 93 |
| Ambrosino[97], (2009) | 27 | Median 36 (25-60) Gy/3 | 13 | 74 crude2 |
| Rusthoven[62], (2009) | 47 | 36-60, 60 Gy/3 | 16 | 92 |
| Lee[98], (2009) | 68 | Median 41.8 Gy/6 | 10.8 | 712 |
| Méndez Romero[93], (2006) | 171 | 30-37.5 Gy/2 |  | 86 |
| Stintzing[99], (2010) | 361 | 24 Gy/l | 21.3 | 872 |
| Goodman[100], (2010) | 261 | 18-30 Gy/l | 17 | 772 |
| Rule[63], (2011) | 27 | 30 Gy/5  50 Gy/5  60 Gy/5 | 20 | 56  89  100 |
| Janoray[101], (2014) | 56 | 45 Gy/3-60 Gy/3 | 12.5 | 642 |

1Included hepatocellular patients 212-18 mo local control percentage.

**Table 3 Summary of dose constraints by number of fractions**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Organ at Risk** | **3 fraction (RAS Trial[102])** | **5 fraction (RTOG 1112[103])** | **QUANTEC (1.8-2 Gy per fraction)[104]** | **Toxicity** |
| Liver excluding CTV | 700 mL < 15 Gy | V 10 < 70% | D mean < 30 Gy | Radiation induced liver dysfunction |
| Esophagus | D 1 mL < 21 Gy | D 0.5 mL < 32 Gy | V 35 < 50% | Esophagitis |
| Stomach | D 1 mL < 21 Gy | D 0.5 mL < 30 Gy | D 100 < 35 Gy | Ulceration |
| Kidney | D 35% < 15 Gy | D mean < 10 Gy | D mean < 28 Gy  (1.8-2 Gy per fraction) | Renal dysfunction |
| Bowel and duodenum | D 1 mL < 21 Gy | D 0.5 mL < 30 Gy | D 45 < 195 cc | Enteritis/fistula |
| Spinal cord | Dmax < 18 Gy | D 0.5 mL < 25 Gy | Dmax = 45 | Myelopathy |
| Heart | D 1 mL, 30 Gy | D 30 mL < 30 Gy | V 25 < 10% | Pericarditis |